A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

April 11, 2026

Study Completion Date

May 11, 2027

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

camrelizumab

"TAE: 3-15ml iodized oil;~HAIC: Indurating arterial catheter, oxaliplatin 85mg/m\^2 D1, arterial infusion, lasting 1-2 hours (d1), LV 400mg/m\^2, arterial infusion, lasting 2-3 hours (d1), 5-Fu 400mg/m\^2, arterial infusion, lasting 3 hours (d1), and fluorouracil 2400 mg/m\^2 for 24-48h;~camrelizumab: 200mg, ivgtt, 30 min (not less than 20 min, not more than 60 min) every 3 weeks (21 days);~apatinib mesylate: 250mg, once a day, taken orally (the time of daily administration should be as much as possible), with warm water.Stop for 3 days before next cycle intervention.~Camrelizumab was given intravenously 1 day before TAE+HAIC treatment for each cycle, TAE+HAIC treatment was given on the second day, and oral apatinib was started after discharge."

Trial Locations (1)

Unknown

RECRUITING

Xinhua Chen, Fuzhou

All Listed Sponsors
lead

Fujian Medical University

OTHER